Skip to content
RDL
Network
Ekosistem
Uygulama değiştir
EN
Hakkımızda
SSS
Giriş yap
Başla
Multiple myeloma triplet therapies: baseline characteristics and control groups – Authors' reply — Sebastian Grosicki (2021) | RDL Network
Back
Cite
Save
Save for later
Share
Home
Publications
Multiple myeloma triplet therapies: baseline characteristics and control groups – Authors' reply
Shared by
Meletios A Dimopoulos
Multiple myeloma triplet therapies: baseline characteristics and control groups – Authors' reply
Letter
2021
en
Authors
+3 more
SG
Sebastian Grosicki
PM
Philippe Moreau
MK
Michael Kauffman
Discussion
(0)
Sign in
to like and join the discussion.
No comments yet. Be the first to comment.
Related publications
Letter
2017
Carfilzomib for relapsed or refractory multiple myeloma – Authors' reply
Meletios A Dimopoulos
,
Amy Kimball
Article
2009
Targeted therapies in multiple myeloma
Efstathios Kastritis
,
Andreas Charidimou
,
Andreas Varkaris
,
Meletios A Dimopoulos
Letter
2016
Carfilozomib versus bortezomib for relapsed or refractory myeloma – Authors' reply
Meletios A Dimopoulos
,
Philippe Moreau
,
Antonio Palumbo
,
Wee Joo Chng
,
Shibao Feng
Letter
2020
Triple artemisinin-based combination therapies for malaria: proceed with caution – Authors' reply
Rob W. van der Pluijm
,
Aung Pyae Phyo
,
Dysoley Lek
,
Sir Nicholas White
,
Arjen M. Dondorp
The Lancet
Letter
2019
Towards global elimination of cervical cancer in all groups of women – Authors' reply
Kate T. Simms
,
Julia Steinberg
,
Michael Caruana
,
Megan A. Smith
,
Jie‐Bin Lew
,
Isabelle Soerjomataram
,
Philip E. Castle
,
Freddie Ian Bray
,
Karen Canfell
Discussion(0)
No comments yet. Be the first to comment.